Abbott and Boston Scientific dominate the $4.6 billion drug-eluting stent market

August 9, 2011 by MassDevice staff

Abbott Labs and Boston Scientific together make up about 64 percent of U.S. drug eluting stent market.

Updated: 8/10/11 9:30 a.m.

Boston Scientific

 Abbott Laboratories (NYSE:ABT) and Boston Scientific Corp. (NYSE:BSX) came out as the big players in the U.S. drug-eluting stent market, together staking claim to more than half of all DES revenues.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.